Visual hallucinations and illusions in Parkinson's disease: the role of ocular pathology.
Hallucinations
MRI
Neuro-ophthalmology
Parkinson’s disease
Retina
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
09
04
2020
accepted:
14
05
2020
revised:
12
05
2020
pubmed:
25
5
2020
medline:
21
5
2021
entrez:
25
5
2020
Statut:
ppublish
Résumé
Whether different mechanisms, particularly ocular pathology, could lead to the emergence of visual hallucinations (VH) (defined as false perceptions with no external stimulus) versus visual illusions (VI) (defined as a misperception of a real stimulus) in Parkinson's disease (PD) remains debated. We assessed retinal, clinical and structural brain characteristics depending on the presence of VH or VI in PD. In this case-control study, we compared retinal thickness using optical coherence tomography (OCT), between PD patients with: VI (PD-I; n = 26), VH (PD-H; n = 28), and without VI or VH (PD-C; n = 28), and assessed demographic data, disease severity, treatment, anatomical and functional visual complaints, cognitive and visuo-perceptive functions and MRI brain volumetry for each group of PD patients. Parafoveal retina was thinner in PD-H compared to PD-C (p = 0.005) and PD-I (p = 0.009) but did not differ between PD-I and PD-C (p = 0.85). Multivariate analysis showed that 1/retinal parafoveal thinning and total brain gray matter atrophy were independently associated with the presence of VH compared to PD-I; 2/retinal parafoveal thickness, PD duration, sleep quality impairment and total brain gray matter volume were independent factors associated with the presence of VH compared to PD-C; 3/anterior ocular abnormalities were the only factor independently associated with the presence of illusions compared to PD-C. These findings reinforce the hypothesis that there may be different mechanisms contributing to VH and VI in PD, suggesting that these two entities may also have a different prognosis rather than simply lying along a continuous spectrum. Clinicaltrials.gov number NCT01114321.
Identifiants
pubmed: 32447550
doi: 10.1007/s00415-020-09925-x
pii: 10.1007/s00415-020-09925-x
doi:
Banques de données
ClinicalTrials.gov
['NCT01114321']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2829-2841Subventions
Organisme : Fondation de France
ID : 76354